GO
Loading...

Vertex Pharmaceuticals Inc

More

  • US stocks rally on Fed minutes, earnings news Wednesday, 9 Apr 2014 | 9:16 AM ET

    NEW YORK— Once again, it was the Federal Reserve to the rescue for the stock market. Facebook rose the most in the S&P 500, jumping 7.3 percent, followed closely by biotech company Vertex Pharmaceuticals, up 7 percent.

  • Investors shed tech, biotech stocks Tuesday, 8 Apr 2014 | 6:22 PM ET

    NEW YORK— Wall Street's cool kids have been booted from the lunchroom. Twitter is down 35 percent since early March and Amazon.com has slid 19 percent. Gilead Sciences is down 16 percent and Vertex Pharmaceuticals has fallen 23 percent.

  • Wall St Week Ahead-Momentum names may see more pain Friday, 4 Apr 2014 | 9:04 PM ET

    Familiar names such as Netflix, Facebook and Tesla Motors, along with a number of biotechnology and cloud-computing stocks, have been pummeled in the last month. Facebook Inc, for example, has fallen nearly 22 percent from an intraday record reached less than a month ago.

  • *S&P 500 rises in Q1 for its fifth straight quarterly gain. NEW YORK, March 31- U.S. stocks rose on Monday, with the S&P 500 ending both March and the first quarter of 2014 with moderate gains, after Federal Reserve Chair Janet Yellen relieved concerns about a rate hike coming earlier than expected.

  • *S&P on track for fifth straight quarterly advance. NEW YORK, March 31- U.S. stocks rose on Monday, with the S&P 500 on track to end the first quarter of 2014 with slight gains, after Federal Reserve Chair Janet Yellen calmed concerns about a rate hike coming earlier than expected. Micron Tech climbed 7.2 percent to $23.48 while Oracle Corp added 3.6 percent to $40.98.

  • Several insurers, including Molina Healthcare, which administer health plans for California's Medicaid program for the poor are asking states to step in and pay for Gilead Sciences Inc's Sovaldi, a drug that costs $84,000 per patient.

  • Twin U.S. studies unlock mystery of how HIV causes AIDS Thursday, 19 Dec 2013 | 2:54 PM ET

    CHICAGO, Dec 19- U.S. scientists have discovered the basic mechanisms that allow HIV to wipe out the body's immune system and cause AIDS, which could lead to new approaches to treatment and research for a cure for the disease that affects 35 million people around the world.

  • *Company to discuss approval expansion with FDA in early 2014. Dec 19- Vertex Pharmaceuticals Inc's Kalydeco cystic fibrosis drug failed to meet the main goal of a late-stage study aimed at expanding its use into patients with a specific gene mutation associated with the rare, life-threatening lung disease, the company said on Thursday.

  • Dec 19- Vertex Pharmaceuticals Inc said on Thursday that ivacaftor, an experimental drug to treat cystic fibrosis, failed to meet its targeted treatment goal in a late-stage study in people aged 6 and older with the "R117H" gene mutation. Shares fell to $64.20 in pre-market trading, a decline of 6.4 percent from a close of $68.63.

  • LONDON, Nov 22- European regulators have recommended approval of a new drug from Gilead Sciences to treat hepatitis C and an HIV medicine from GlaxoSmithKline, both of which are expected to be major sellers.

  • Midday movers: Yahoo, Cummins, TriQuint & more Tuesday, 29 Oct 2013 | 12:43 PM ET

    Take a look at some of Tuesday's midday movers:

  • Oct 29- Vertex Pharmaceuticals Inc lowered its full-year revenue forecast and said it would cut about 15 percent of its workforce after sales of its hepatitis C drug plunged in the third quarter. The company's hepatitis C treatment, Incivek, was hugely popular when it was launched in May 2011 and revenue from the drug topped $1 billion in a few months.

  • Vertex cuts jobs, forecast as hep C drug sales plunge Tuesday, 29 Oct 2013 | 8:39 AM ET

    Oct 29- Vertex Pharmaceuticals Inc lowered its full-year revenue forecast and said it would cut about 370 jobs after sales of its hepatitis C drug plunged in the third quarter. The company said it now expects full-year revenue in the range of $1 billion to $1.05 billion, down from its previous forecast of $1.1 billion to $1.2 billion.

  • J&J's new hepatitis C drug gets positive FDA review Tuesday, 22 Oct 2013 | 11:42 AM ET

    Oct 22- A new hepatitis C drug made by Johnson& Johnson showed an acceptable safety profile in clinical trials, reviewers for the U.S. Food and Drug Administration said on Tuesday. J&J shares were up nearly 1 percent to $92 in morning trade on the New York Stock Exchange.

  • These stocks are getting hit hardest in selloff Wednesday, 9 Oct 2013 | 11:00 AM ET

    Volatility is up more than 50 percent since the S&P 500 hit a record price of 1,729.86 last month.

  • Early movers: LULU, NFLX, ALL, RCL, MW, P & more Thursday, 12 Sep 2013 | 7:50 AM ET

    Some of the names on the move ahead of the open.

  • Early movers: MRK, PFE, GNRC, HMA, CYH & more Tuesday, 30 Jul 2013 | 8:11 AM ET

    Some of the names on the move ahead of the open.

  • Early movers: SBUX, AMZN, NWL, HAL & more Friday, 26 Jul 2013 | 7:56 AM ET

    Some of the names on the move ahead of the open.

  • Top Undervalued Pharma Stock: Analyst Monday, 29 Apr 2013 | 1:23 PM ET

    One biotech name has the best upside potential for 2013, pharmaceutical analyst Barbara Ryan says.

  • Stocks End Up, But Log Worst Weekly Drop in 2013 Friday, 19 Apr 2013 | 4:32 PM ET

    Stocks reversed a two-day slump to close out the week on a positive note, with the S&P 500 rebounding after finishing below it 50-day moving average for the first time this year, but all three major averages still logged their worst weekly drop this year.

Most Popular Video

Thursday, 17 Apr 2014 | 1:03 PM ET

Dissecting the current market action amid geopolitical concerns, with Kenny Polcari, O'Neil Securities, and CNBC's Dominic Chu.

Thursday, 17 Apr 2014 | 12:06 PM ET

Discussing the case for stocks, with Ed Yardeni, president and chief investment strategist of Yardeni Research. He thinks the market had an "internal correction."

Thursday, 17 Apr 2014 | 1:00 PM ET

Secretary of State John Kerry comments after a meeting in Geneva with Russian Foreign Minister Sergey Lavrov and representatives of the EU and Ukraine.